157 related articles for article (PubMed ID: 36428810)
1. Oocyte Quality Assessment in Breast Cancer: Implications for Fertility Preservation.
Fabiani C; Guarino A; Meneghini C; Licata E; Paciotti G; Miriello D; Schiavi MC; Spina V; Corno R; Gallo M; Rago R
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428810
[TBL] [Abstract][Full Text] [Related]
2. Female fertility preservation: Impact of cancer on ovarian function and oocyte quality.
Fabiani C; Ferrante MG; Meneghini C; Licata E; Paciotti G; Gallo M; Schiavi M; Spina V; Guarino A; Caserta D; Rago R
Int J Gynaecol Obstet; 2022 Jan; 156(1):166-171. PubMed ID: 33837528
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
4. Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation.
Almog B; Azem F; Gordon D; Pauzner D; Amit A; Barkan G; Levin I
Fertil Steril; 2012 Oct; 98(4):957-60. PubMed ID: 22763097
[TBL] [Abstract][Full Text] [Related]
5. BRCA1/2 gene mutations do not affect the capacity of oocytes from breast cancer candidates for fertility preservation to mature in vitro.
Grynberg M; Dagher Hayeck B; Papanikolaou EG; Sifer C; Sermondade N; Sonigo C
Hum Reprod; 2019 Feb; 34(2):374-379. PubMed ID: 30561604
[TBL] [Abstract][Full Text] [Related]
6. Response to ovarian stimulation in patients facing gonadotoxic therapy.
Johnson LN; Dillon KE; Sammel MD; Efymow BL; Mainigi MA; Dokras A; Gracia CR
Reprod Biomed Online; 2013 Apr; 26(4):337-44. PubMed ID: 23415997
[TBL] [Abstract][Full Text] [Related]
7. Prior salpingectomy impairs the retrieved oocyte number in in vitro fertilization cycles of women under 35 years old without optimal ovarian reserve.
Ho CY; Chang YY; Lin YH; Chen MJ
PLoS One; 2022; 17(5):e0268021. PubMed ID: 35507603
[TBL] [Abstract][Full Text] [Related]
8. The impact of letrozole administration on oocyte morphology in breast cancer patients undergoing fertility preservation.
Bercaire LMN; Cavagna M; Donadio NF; Rocha AR; Portela R; Alves VR; Santos TBB; Cavagna F; Dzik A; Gebrim LH; Nahas EAP
JBRA Assist Reprod; 2020 Jul; 24(3):257-264. PubMed ID: 32293820
[TBL] [Abstract][Full Text] [Related]
9. Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer.
Porcu E; Cillo GM; Cipriani L; Sacilotto F; Notarangelo L; Damiano G; Dirodi M; Roncarati I
J Assist Reprod Genet; 2020 Mar; 37(3):709-715. PubMed ID: 31872386
[TBL] [Abstract][Full Text] [Related]
10. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers.
Goldrat O; Van Den Steen G; Gonzalez-Merino E; Dechène J; Gervy C; Delbaere A; Devreker F; De Maertelaer V; Demeestere I
Reprod Biol Endocrinol; 2019 Jan; 17(1):3. PubMed ID: 30606204
[TBL] [Abstract][Full Text] [Related]
11. The ovarian response in fragile X patients and premutation carriers undergoing IVF-PGD: reappraisal.
Avraham S; Almog B; Reches A; Zakar L; Malcov M; Sokolov A; Alpern S; Azem F
Hum Reprod; 2017 Jul; 32(7):1508-1511. PubMed ID: 28472405
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
13. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
[TBL] [Abstract][Full Text] [Related]
14. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M
Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109
[TBL] [Abstract][Full Text] [Related]
15. The use of GnRH-agonist trigger for the final maturation of oocytes in normal and low responders undergoing planned oocyte cryopreservation.
Maslow BL; Guarnaccia M; Stefanacci C; Ramirez L; Klein JU
Hum Reprod; 2020 May; 35(5):1054-1060. PubMed ID: 32406915
[TBL] [Abstract][Full Text] [Related]
16. [Smoothing Gan Reinforcing Shen Method Adjuvantly Treated Poor Response of Diminished Ovari- an Reserve Patients in in vitro Fertilization and Embryo Transfer: a Clinical Study].
Zhang Z; Zhang XH; He TY
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Oct; 35(10):1170-4. PubMed ID: 26677665
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Oocyte and Embryo Quality Between Random Start and Controlled Ovarian Stimulation Cycles in Cancer Patients Undergoing Fertility Preservation.
İsrafilova G; Şükür YE; Özkavukcu S; Sönmezer MA; Atabekoğlu CS; Özmen B; Berker B; Aytaç R; Koç A; Sönmezer M
Reprod Sci; 2021 Aug; 28(8):2200-2207. PubMed ID: 33409878
[TBL] [Abstract][Full Text] [Related]
18. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.
Abir R; Ben-Aharon I; Garor R; Yaniv I; Ash S; Stemmer SM; Ben-Haroush A; Freud E; Kravarusic D; Sapir O; Fisch B
Hum Reprod; 2016 Apr; 31(4):750-62. PubMed ID: 26848188
[TBL] [Abstract][Full Text] [Related]
19. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation.
Gunnala V; Fields J; Irani M; D'Angelo D; Xu K; Schattman G; Rosenwaks Z
Fertil Steril; 2019 Feb; 111(2):363-371. PubMed ID: 30527950
[TBL] [Abstract][Full Text] [Related]
20. Impact of BRCA mutations and hormone receptor status on reproductive potential in breast cancer patients undergoing fertility preservation.
Kim SW; Kim TH; Han JY; Kim SK; Lee JR; Jee UC; Suh CS; Kim SH
Gynecol Endocrinol; 2022 Mar; 38(3):227-230. PubMed ID: 34775902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
